文献速递姑息放疗与转移瘤放疗物理与技术

大体积肿瘤空间分割放疗的系统综述:临床结局与剂量学挑战

Spatially fractionated radiation therapy for bulky tumors: a systematic review of clinical outcomes and dosimetric challenges.
PubMed 文献 · Radiat Oncol · 2026-05-22

SFRT主要用于姑息治疗(216例),约80%病灶报告肿瘤缩小且症状缓解一致,毒性多为1-2级,但剂量学参数和分次方案异质性显著。

要点

  • SFRT治疗大体积肿瘤约80%病灶肿瘤缩小,症状缓解一致
  • 毒性多为1-2级,≥3级严重毒性罕见
  • 剂量学参数与分次方案异质性大,缺乏标准化

核心结论

  • SFRT对大体积肿瘤是可行且有效的选择,尤其适用于姑息治疗场景。
  • 缺乏剂量学标准化及前瞻性数据,需统一方案和精心设计的临床试验。

研究设计与样本

  • 系统综述,检索MEDLINE数据库2010年1月至2025年6月发表的英文文献。
  • 纳入报告SFRT原始临床数据的病例报告、病例系列、回顾性分析和前瞻性试验。
  • 采用ROBINS-I框架评估方法学质量。

主要发现

  • 最常见治疗部位为胸部(28.8%)、盆腔(24.7%)和腹部(23.3%)。
  • 主要组织学类型为肉瘤(48.0%)、癌(14.5%)和非小细胞肺癌(10.4%)。
  • SFRT主要以姑息意图实施(216例)。
  • 约80%病灶报告肿瘤缩小,症状缓解一致。
  • 治疗相关毒性一般较轻,多数不良事件为1-2级,≥3级严重毒性罕见。

关键数值与推荐

  • SFRT包括GRID和Lattice放疗(LRT),通过刻意不均匀剂量分布克服正常组织耐受限制。

临床怎么用

  • SFRT可作为大体积肿瘤的姑息治疗选择,预期肿瘤缩小和症状缓解且毒性较轻。
  • 临床实施时需注意剂量学参数(如谷峰剂量比)和分次方案缺乏统一标准。

局限性

  • 研究间剂量学参数和分次方案存在显著异质性。
  • 缺乏剂量学标准化和前瞻性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Conventional radiotherapy for bulky tumors is often limited by normal tissue tolerance, restricting dose escalation and increasing toxicity. Spatially Fractionated Radiation Therapy (SFRT), including GRID and Lattice Radiotherapy (LRT), delivers intentionally heterogeneous dose distributions to overcome these limitations. This systematic review summarizes the clinical application, outcomes, and dosimetric variability of SFRT in the treatment of bulky tumors. A systematic literature search of the MEDLINE database was performed for studies published between January 2010 and June 2025. Eligible English-language studies reporting original clinical data on SFRT, including case reports, case series, retrospective analyses, and prospective trials, were included. Data on patient and tumor characteristics, treatment intent, SFRT technique, clinical response, and toxicity were extracted, and methodological quality was assessed using the ROBINS-I framework. Twenty-nine studies involving 513 patients and 553 lesions were included. The most commonly treated sites were the thorax (28.8%), pelvis (24.7%) and abdomen (23.3%), with sarcomas (48.0%) carcinomas (14.5%) and non-small cell lung cancer (10.4%) being the predominant histologies. SFRT was mainly delivered with palliative intent (216 cases). Tumor shrinkage was reported in approximately 80% of lesions, with consistent symptom relief. Treatment-related toxicity was generally mild, with most adverse events graded as 1-2; severe toxicities (Grade ≥ 3) were rare. Despite favorable clinical outcomes and an acceptable safety profile, substantial heterogeneity in dosimetric parameters, including valley-to-peak dose ratio and fractionation schemes, was observed across studies. SFRT appears to be a feasible and effective option for bulky tumors, particularly in the palliative setting. However, the lack of dosimetric standardization and prospective data highlights the need for harmonized protocols and well-designed clinical trials.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Di Franco R, Mottareale R, Pezzulla D, et al. Spatially fractionated radiation therapy for bulky tumors: a systematic review of clinical outcomes and dosimetric challenges. Radiat Oncol. 2026. PMID: 42174670. doi:10.1186/s13014-026-02860-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。